Abbott has received FDA clearance for the FreeStyle Libre 3 Plus, extending the world's best-selling continuous glucose monitor to 15 days of wear with improved accuracy and a redesigned 0.4mm sensor filament.
Abbott has announced FDA clearance for the FreeStyle Libre 3 Plus, an extended-wear continuous glucose monitoring (CGM) system that maintains real-time glucose readings for 15 consecutive days — up from 14 days on the original Libre 3.
The new sensor features a re-engineered 0.4mm filament with improved wetting chemistry that delivers a Mean Absolute Relative Difference (MARD) of 7.5%, making it the most accurate factory-calibrated CGM on the market.
New Features vs. Libre 3
- 15-day wear (vs. 14 days)
- MARD 7.5% (improved from 7.9%)
- Redesigned auto-applicator: 41% smaller
- Real-time alarms for low/high glucose
- Direct Bluetooth to iPhone and Android without reader
- Compatible with LibreLink, LibreLinkUp and 3rd-party apps
Abbott estimates over 6.5 million people in the US use the FreeStyle Libre system. The Libre 3 Plus is expected to launch commercially in Q2 2026, priced comparably to the Libre 3 at approximately $129 for a 2-pack.
The clearance covers Type 1 and Type 2 diabetes in patients aged 2 years and older.
